Induction Regimen Options for Patients with Transplant-Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

Video

Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.

Related Videos
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Michael Leung, PharmD, an expert on colorectal cancer
A panel of 4 experts on colorectal cancer
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Saad Z. Usmani, MD, MBA, FACP, FASCO, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center
Video 2 - "Targeting RET Fusion in Brain Tumor"